ASCO 2021: Pembrolizumab shows promise for adjuvant treatment of renal cell carcinoma
Immunotherapy with pembrolizumab after surgery significantly improves disease-free survival among patients with the most prevalent form of kidney cancer, clear-cell renal carcinoma. Researchers reported this finding on June […]
